GTC Biotherapeutics (fka GTCB)

[shears]

I bet AT has a lot lower risk of brain bleeds than the thrombolytics, plus the anti-inflammatory aspects. Sounds like a great potential market for AT, bigger than anything else contemplted so far. Baby boomers are starting to have strokes. As I see it AT is the perfect agent to reduce thrombosis risk without increasing bleeding risk compared to the alternatives and it seems to me that any sort of deficiency of AT either congenital or aquired is a very bad bad thing. I will hold my paltry shares till the end, whatever that is but I'm not buying more because of the schleps running the company. Bad fiscal management - too much being given away and too much dilution to 'survive'. I like the science but that is never enough.